Skip to main content

Home/ health information/ Group items tagged API

Rss Feed Group items tagged

sara01james

Veterinary API Manufacturing Market Worth $10.4 Billion By 2028 - 0 views

  •  
    The global veterinary active pharmaceutical ingredients manufacturing market size was valued at USD 6.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.9% from 2021 to 2028
pharmacybiz

Pharmaceutical Industry: 6 Interesting Things Should Know - 0 views

  •  
    The pharmaceutical industry is one of the most important and valuable industries in the world. It is responsible for developing and producing medicines that improve and save lives. However, there are some things you may not know about this fascinating industry. In this blog post, we will discuss six interesting facts about the pharmaceutical industry! 1. THE MANUFACTURING PROCESS OF PHARMACEUTICALS IS HIGHLY REGULATED All pharmaceutical products must go through a rigorous manufacturing process before they can be made available to patients. This process is heavily regulated by various government agencies to ensure that the medicines are safe and effective. The pharmaceutical manufacturing process usually involves multiple steps, including the preparation of raw materials, the manufacturing of active pharmaceutical ingredients (APIs), and the packaging and labeling of finished products. To ensure patient safety, all pharmaceutical companies must adhere to strict regulations set by government agencies such as the Food and Drug Administration (FDA). These regulations are designed to protect patients by ensuring that medicines are safe and effective.
pharmacybiz

Drug shortage: Fixing the medicines shortage crisis - 0 views

  •  
    From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among patients, the government, and the wider pharma industry. Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine, and soaring input costs weighing on manufacturers. More recently, a sudden spike in respiratory infections - another by-product of Covid-19 that neither pharma companies nor the government were able to predict - has deepened the crisis, with 70 commonly taken drugs out of stock in Britain as of February. The problem is not unique to the UK. In a recent survey of groups representing pharmacies in 29 European countries, three quarters said shortages were worse this winter than a year ago, with a quarter reporting more than 600 drugs in short supply. The US is also facing significant shortages of popular prescription drugs like amoxicillin and Adderall, an ADHD medication. To some extent, the current disruption is laying bare wider challenges facing the industry for several years that were only exacerbated by the pandemic. The over-reliance on foreign suppliers for most active pharmaceutical ingredients (APIs) is one of them. This model has left companies more susceptible to supply shocks, which have in turn increased in frequency and severity due to pandemic lockdowns, the war in Ukraine and other issues such as the shortage of shipping containers. Pharma's long and opaque supply chains, alongside regulatory complexities, also mean it is taking longer for drugmakers to reconfigure manufacturing and distribution in times of additional need.
pharmacybiz

GSK Invests £200 Million to Boost UK Pharma Manufacturing - 0 views

  •  
    British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.
ind swift

Quality Products In Pharma Industry | Drug Research and Development | Pharmaceutical Pr... - 0 views

  •  
    Possess state-of-the-Art manufacturing facilities for finished Dosage Forms & API's conforming to the most Stringent International Norms WHO-GMP, TGA (Australia), MHRA (UK). Manufacturing capacity (Finished Dosage) : 2300 million Tablets 64 million Ampoules 27 million Vials 84 million Capsules 18 million Dermatological products 62 million Oral liquid bottles Manufacturing capacity (API) : 1,50,0000 (15 lakhs) sq.
1 - 5 of 5
Showing 20 items per page